What is GenoSpace?
GenoSpace operates as a sophisticated precision medicine platform designed to integrate clinical and genomic data into actionable insights for oncologists. The company addresses the persistent friction in clinical trial recruitment by offering advanced tools for patient matching, EMR-to-EDC integration, and data-driven site selection. By focusing on community-based oncology practices, GenoSpace effectively democratizes access to innovative cancer therapies, ensuring that clinical research is not siloed within academic centers but is accessible to a wider patient population. Their technology stack is engineered to streamline the complex workflows inherent in modern oncology, ultimately driving higher patient accrual rates and improving the efficiency of clinical trial operations.
How much funding has GenoSpace raised?
GenoSpace has raised a total of $5M across 1 funding round:
Private Equity
$5M
Private Equity (2014): $5M with participation from Thomson Reuters
Key Investors in GenoSpace
Thomson Reuters
Thomson Reuters is a global leader in professional information services, providing technology solutions and industry-leading content to support decision-making in complex sectors like healthcare and law.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for GenoSpace?
With this major strategic investment, GenoSpace is expected to deepen its integration within the oncology ecosystem, focusing on the expansion of its clinical-genomic data capabilities. The company will likely prioritize the enhancement of its automated trial matching algorithms and the scaling of its site selection services to meet the growing demand for personalized medicine. As the industry shifts toward more data-centric research models, GenoSpace is well-positioned to capitalize on the increasing need for interoperable healthcare systems that can translate complex genomic findings into real-time clinical decisions. Future growth will likely involve expanding its footprint in community oncology, further solidifying its role as an essential partner for research institutions and pharmaceutical developers alike.
See full GenoSpace company page
